“Sasha is one of most pleasant persons i have ever worked with. she brings life to any team and improves the overall productivity of the team by virtue of her interactions. She has excellent project management skills and also is one who is willing to learn from others. I can confidently state that she would be any asset to any company with her overall skills, personality and willingness to learn.”
Sasha Stann, CCRP
Sudbury, Massachusetts, United States
2K followers
500+ connections
2K followers
500+ connections
About
Hands on clinical operations professional. Strong experience successfully managing &…
Activity
-
During my thirteen-year journey with IDBS, I grew to consider many as trusted colleagues and friends. Working in Professional Services and…
During my thirteen-year journey with IDBS, I grew to consider many as trusted colleagues and friends. Working in Professional Services and…
Liked by Sasha Stann, CCRP
-
When in Houston, team building is a must! #DrugConjugatesForGlobalPatients
When in Houston, team building is a must! #DrugConjugatesForGlobalPatients
Shared by Sasha Stann, CCRP
-
Michael Gaviria, Sr. CTA started today Pleased to welcome our 11th employee at MediLink Therapeutics!
Michael Gaviria, Sr. CTA started today Pleased to welcome our 11th employee at MediLink Therapeutics!
Shared by Sasha Stann, CCRP
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
Landmark Worldwide
-
Coursework (2014-2020):
Landmark Forum (3x), Advanced Course (3x), Self Expression & Leadership (SELP), Seminar (Excellence: In the Zone), Introduction Leaders Program (successful completion), Communication Course (Access to Power) and The Being a Leader and the Effective Exercise of Leadership Course (Cancun, Mexico)
Coached (2017-2018):
Introduction Leaders program (2x) -
-
Volunteer Experience
-
Volunteer
Quincy Animal Shelter
- 1 year 1 month
Animal Welfare
Walked dogs, fed & played with cats, cleaned the kennels & cat crates, assisted with feedings, & helped with laundry.
-
Big Sister volunteer
Big Brother Big Sister Foundation
- 6 years
Children
As a big sister I worked closely with one little girl for close to 6 years. I provided mentorship & guidance. Activities included: hiking, cooking, snowboarding, going to museums, concerts, visits to the beach, reading, movies etc.
Patents
-
Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics
Filed US 13787365.9 - 1403 PCT/US2013040785
Courses
-
University of Salamanca, International summer semester abroad, 2000
-
Recommendations received
1 person has recommended Sasha
Join now to viewMore activity by Sasha
-
The 10th US employee started at MediLink today! Pleased to welcome Angie Cai, representing medical! #USTeamGrows
The 10th US employee started at MediLink today! Pleased to welcome Angie Cai, representing medical! #USTeamGrows
Shared by Sasha Stann, CCRP
Other similar profiles
Explore more posts
-
Jim Anthony
Project Optimus is revolutionizing early oncology trials, aiming to ensure more effective and safer cancer drugs and improve patients' quality of life. Parexel experts have identified three strategies to help sponsors overcome challenges in achieving dose-optimization requirements. Here’s what we know works: 1️⃣ Design an integrated first-in-human study 2️⃣ Reach agreement with FDA at each step 3️⃣ Challenge guidelines with a compelling rationale Let me know your thoughts below and read more in our New Medicines, Novel Insights report! https://lnkd.in/dmYADu-n #ProjectOptimus #Oncology #NovelInsights
-
iOmx Therapeutics AG
We look forward to hearing Christine Rothe, CDO of iOmx, speak at the 6th Annual Macrophage-Directed Therapies Summit in Boston on October 2nd. Christine will provide key insights into IOMX-0675, our highly differentiated, fully human, cross-specific antibody targeting LILRB1 and LILRB2. In the presentation, Christine will discuss how IOMX-0675 effectively repolarizes the tumor microenvironment, resulting in potent tumor cell killing both 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 and 𝘪𝘯 𝘷𝘪𝘷𝘰. Also, Christine will highlight IOMX-0675's unique binding profile, which selectively antagonizes the immunosuppressive receptors LILRB1 and LILRB2 while sparing the immuno-activating family members. This differentiation results in superior macrophage repolarization and immune cell activation compared to other antibodies. 🔬 📢 Stay tuned for further updates! Hanson Wade Group #CancerResearch #Macrophages #immunotherapy #ImmunoOncology
-
Vincent Zucconi
🎉 Big News from NeoGenomics Laboratories! 🧬💡 NeoGenomics just secured New York State Department of Health approval for its Neo Comprehensive and NeoType DNA & RNA Lung NGS tests! 🎯 These advanced tests are now available to oncologists in New York, aiming to enhance diagnostic precision and cost-effectiveness for cancer treatment. The Neo Comprehensive panel covers 517 genes across multiple tumors, while NeoType focuses on actionable mutations in lung cancer. #CancerResearch #NGSTesting #LungCancer #PrecisionOncology #NeoGenomics #InnovationInHealthcare #Genomics #PersonalizedMedicine
1 Comment -
uBriGene Biosciences Inc.
🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!
-
Shawn Barley
Attention Life Science Professionals! 🔥 ANOTHER HOT TOPIC ALERT! 🧪🔬 Some More Good News in the Life Sciences! Check out the summary below regarding the 3,000 jobs created in Boston area in 2024. Share your thoughts in the comments! And if you are looking for folks, please let us know! hashtag #lifesciences #biotech #pharma #medicaldevice #diagnostics #hiring2024 #boston The Richmond Group USA
-
Venus Labrador
Discover the latest enhancements to Labcorp Global Trial Connect, designed to streamline site workflows and boost clinical trial efficiency. These updates, driven by insights from collaboration with sponsors and sites, aim to empower investigator sites to focus more on what truly matters, patient care. Your commitment to patient care is why we’re committed to redefining clinical trial delivery. Learn more: https://lnkd.in/eavYncMz #ClinicalTrials #GlobalTrialConnect
-
Raphael Gübeli
🚀 BIOPROCESSING SUMMIT 📅 Monday August 19, 12:00 PM 📍Gene Therapy CMC and Analytics Track Do not miss the opportunity to visit my Luncheon Presentation during the #CHIBioprocessingSummit in Boston: 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗲𝗱 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: 𝗧𝗵𝗲 𝗠𝗮𝗸𝗶𝗻𝗴-𝗢𝗳 𝗗𝗘𝗡𝗔𝗥𝗔𝗦𝗘 𝗛𝗶𝗴𝗵 𝗦𝗮𝗹𝘁 𝗳𝗼𝗿 𝗛𝗶𝗴𝗵-𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 𝗗𝗡𝗔 𝗥𝗲𝗺𝗼𝘃𝗮𝗹 𝗶𝗻 𝗩𝗶𝗿𝗮𝗹 𝗩𝗲𝗰𝘁𝗼𝗿 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 👇Session Objectives: 🔎 How to improve efficiency of viral vector manufacturing at elevated salt concentrations ✅ The benefits of DENARASE High Salt for DNA removal 🔬 Enzyme engineering at c-LEcta: ENESYZ Technology Platform 📣 Stop also by 𝗕𝗼𝗼𝘁𝗵 𝟱𝟬𝟳 to talk to my colleagues Tim McClain, Jay Lachance and Elena Kempf who will tell you more about 𝗗𝗘𝗡𝗔𝗥𝗔𝗦𝗘 𝗛𝗶𝗴𝗵 𝗦𝗮𝗹𝘁 and our complete toolkit for DNA removal. Cambridge Healthtech Institute #CGT #DENARASE #biopharma #ISCT2024 #enzyme #endonuclease #viralvector #bioprocessing
-
Newcells Biotech Ltd
Join Catherine Ulich (Senior Field Application Specialist) and Anthony Kayas (Account Manger) at Discovery on Target in Boston next week📍 Discovery on Target highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules. Cathrine will be speaking at 9am on 1st October about Accelerating Clinical Translation: Harnessing Biology and Technology with Predictive Models 💡 You can also stop by Booth #212 to speak to our team and find out more about our models! 👋 #Newcells #DiscoveryonTarget #PredictiveModels
-
Iqbal Gandhi
Partnership and collaboration were key in developing the nAbCyte™ CDx assay for determining patient eligibility in the BEQVEZ™ gene therapy program. Today, we’re proud to run sponsored testing programs in the U.S. and Canada, supporting providers as they use this breakthrough to identify patients who may benefit from this novel therapy. Learn more: https://lnkd.in/dirVqgwy #GeneTherapy #CDx
-
Parris Johnson
Looking forward to attending #ASH2024 this year. Let's connect and I can share with you how TD2 can support your next trial. 🔗https://hubs.li/Q02YXgqv0 #HematologyOncology #ClinicalTrials #OncologyCRO #BloodCancerResearch #DrugDevelopment #PrecisionOncology #ClinicalTrialSolutions
-
Grace G.
The fourth quarter of 2024 is critical for the biotech industry, with 5 major FDA approval decisions on the horizon. These upcoming verdicts could impact everything from treatments for #cancer to #rarediseases 🧬 Stay ahead of the latest in #biotech and learn how these #FDA decisions could shape the future of healthcare.
-
Sabrina Johnson
Looking forward to joining fellow industry leaders at this year’s IDDST-International Drug Discovery Sciences & Technology Congress in Budapest! I am particularly excited to discuss how drug development in women’s health can uniquely leverage female biology to customize delivery methods and durations for optimized outcomes. If you are attending or will be in the area, let’s connect and talk all things #womenshealth!
-
Hung Trinh
The year of hard and dedicated support, FDA has provided a comprehensive approval lists. Novel Drug Approvals for 2024 FDA Novel Drug Therapy Approvals for 2024 In 2024, CDER approved 50 new drugs never before approved or marketed in the U.S., known as “novel” drugs. We also made other important approval decisions, such as approving previously approved drugs for new uses and broader patient populations. CDER’s novel drug approvals for 2024 are listed below. For more information, download the report. Vertex Biopharm Consulting https://lnkd.in/e5tyuGk9
1 Comment -
Aimee Joy
Do flu vaccines work? While the vaccine may not prevent you from getting the flu, the CDC maintains that flu vaccines can help reduce the severity of symptoms. Read more about how flu vaccines can help. Visit our website below to learn how Labcorp can help your organization prepare for the flu: https://bit.ly/3vOQyZk
-
PTC Therapeutics, Inc.
PTC was excited to learn, share and collaborate with other leading RNA experts at the recent 7th Annual RNA-Targeted Drug Discovery & Development Summit in Boston, MA, and the RNA at the Bench and Bedside IV conference in La Jolla, CA. Anu Bhattacharyya, Kerstin Effenberger, and Marla Weetall from our research team presented on ways PTC is leveraging its leading splicing platform to identify promising therapies for rare diseases with high unmet need. Learn more about our splicing platform here: https://bit.ly/4fi4w6L
1 Comment -
LucidQuest
LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> FDA's Peter Marks single-handedly approved Sarepta’s gene therapy — what does that mean for everyone else?: Is Sarepta special? Or has the FDA set a new precedent for how it approaches treatments for devastating diseases with few options? On Thursday, the FDA announced it was expanding the allowed use of Sarepta’s gene therapy for Duchenne muscular dystrophy to a far wider group of patients. The treatment, Elevidys, will now be available to those ages 4 and older, an expansion that’s expected to make it available to 80% of patients with the disease, according to the company. But the move by the FDA, in which CBER Director Peter Marks overruled his own staff, is prompting new questions about just how the agency will approach similar drugs in the future. On Monday, ahead of the decision on Sarepta’s gene therapy, Endpoints News asked Marks about disagreement within the FDA. He said there’s a “spectrum” of views within the agency, but “our job as leaders is to help people feel like we’re going to lead them in a place where we get more products across the finish line.” “I’d like to move it from the baseline further towards a little bit of willingness to take risks or a moderate amount more toward taking more risks and hopefully people will come along,” Marks said. “That’s where we’re hoping to head in the coming months to years.” Staff overruled Memos accompanying Thursday’s action showed how Marks overruled two top FDA officials, including his deputy Nicole Verdun — the director of the Office of Therapeutic Products which the agency established last year under Marks to deal with a flood of new cell and gene therapies. Verdun’s lieutenant Lola Fashoyin-Aje recommended rejecting the therapy and running a new clinical trial. Fashoyin-Aje said there wasn’t enough evidence to show benefit in the patient populations for which Sarepta asked for approval, including the initial accelerated approval population of boys ages 4 and 5. Verdun, who like Marks has spoken about working more closely with patient groups, agreed with Fashoyin-Aje’s recommendation. Elevidys failed to meet the primary endpoint last year in a confirmatory study, but Sarepta cited key secondary endpoints suggesting the therapy may improve boys’ ability to stand and walk. In his memo, Marks called the secondary and exploratory data points “compelling,” and called the benefit-to-risk ratio “favorable, taking into consideration the severe unmet need and existing uncertainties.” “I’m just stunned that one person can override the decision of multiple career staff at the FDA with varied expertise,” said Reshma Ramachandran, an assistant professor of medicine at Yale University. “That is troubling to see that sort of power can be wielded this way.” But for patient advocates, Marks’ action… #lucidquest #genetherapy #celltherapy
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More